Romanian and French firms will produce cancer-treatment isotope Lutetium-177 starting 2028.

Romanian nuclear company Nuclearelectrica and French firm Framatome have agreed to produce the cancer-treatment isotope Lutetium-177 at Romania's Cernavodă nuclear plant. This partnership aims to boost the supply of Lutetium-177, crucial for treating various cancers, including prostate cancer, to support global healthcare needs. The companies plan to start producing the isotope by 2028.

November 12, 2024
6 Articles